A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse

Trial Profile

A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Corticotropin (Primary) ; Corticotropin (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt plc
  • Most Recent Events

    • 18 Jun 2018 According to a Mallinckrodt plc media release, data from this trial was presented at the Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC 2018).
    • 08 Jun 2018 Planned number of patients changed from 260 to 160.
    • 01 Jun 2018 Results published in the Mallinckrodt plc Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top